Drug Trial Radar · NCT06846268
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Apr 14, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- National University Hospital, SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Adagene Inc
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Conditions
- Locally Advanced Colorectal Cancer
Interventions
ADG126Drug
Administered via intravenous infusion on Day 1 only (Q6W) or Day 1 and Day 22 (Q3W).
PembrolizumabDrug
Administered via intravenous infusion on Day 1 and Day 22.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Major Pathologic Response (MPR)Time frame: Up to 4 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National University Hospital
Singapore, Singapore · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.